




[Science Education Patient Care & Advocacy](#)  
[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2023](#) [Organisational Structure 2023](#) [Financial Highlights 2023](#) [EBMT Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Donal McLornan  
CMWP Chair  
United Kingdom

## Major achievements

The CMWP has continued to make significant and impactful progress as regards academic output and collaboration over the last twelve months.

We have had **three very successful educational events** this year. The first was a virtual event in January 2023 focused on MDS, VEXAS and overlap syndromes. We

discussed the evolving role of molecular prognostication in MDS to aid allo-HCT decisions (Dr. Marie Robin, Paris, Professor Matteo della Porta, Milan and Dr Nico Gagelmann, Hamburg), a debate on whether all eligible CMMP patients should be offered a 'timely' allo-HCT ( Dr Joanna Drozd-Sokolowska, Warsaw and Dr. Francesco Onida, Milan) and the role of upfront allo-HCT in MDS versus the role of novel agents (Dr. Katja Sockel, Dresden and Professor Pierre Fenaux, Paris). Next we tackled the difficult subject of post-transplant intervention led by Professor Ibrahim Yakoub-Agha, Lille followed by a session focussed on how the field of therapeutic approaches to VEXAS (including allo-HCT) may develop and where allo-HCT will be placed (Professor Arsene Mekinian (Paris), Dr. Carmelo Gurnari (Rome), and chair of the ADWP, Dr. Raffaella Greco (Milan)).

We had an amazing 'full house' **educational session** at the EBMT AGM in Paris focussed on the intricacies and pitfalls of allo-HCT for Myelofibrosis. Finally, the CMWP and CTIWP members were delighted to have a face-to-face meeting in late November in Hamburg led by the chairs Dr. Donal McLornan (CMWP) and Dr Annalisa Ruggeri (CITWP) alongside local host Dr. Nico Gagelmann (Hamburg). This was a state of the art meeting bringing attendees and faculty together to discuss the major progress in immunotherapeutic strategies to address plasma cell dyscrasias. This was alongside an excellent nursing educational program led by Maaïke de Ruijter (Amsterdam).

We have numerous **high impact publications** including international guidelines on Myelofibrosis allo-HCT (EBMT-ELN), the role of germline predisposition traits in allo-HCT for MDS, novel prognostic scores for relapse of MM post auto-HCT and upcoming guidelines on allo-HCT for advanced mastocytosis.

2023 was also a year when the whole CMWP team focused on **study completion** and **prioritisation of meaningful contemporary studies**. We thank everyone involved and, in particular, the principle investigators, subcommittees and the CMWP Data Management/Programming team and statistician experts.

## Principal research studies

[Allo-HCT in CLL after multiple pathway inhibitors.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Chronic Lymphocytic Leukaemia \(CLL\)](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Michel van Gelder/Olivier Tournilhac](#)

[Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Multiple Myeloma \(MM\) or other Plasma Cell Disorder \(PCD\)](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Patrick Hayden](#)

## **Key publications**

[2023](#)

[Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Marie Robin](#)

[Journal](#)

[Br J Haematol.](#)

[2023](#)

[Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

1st listed author

Alicia Rovó

Journal

Am J Hematol.

2023

Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Carmelo Gurnari

Journal

Lancet Haematol.

2023

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Juan Carlos Hernández-Boluda

Journal

Bone Marrow Transplant.

2023

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Roni Tamari


Journal

Blood Adv.

See the full list of the CMWP 2023 publications



Impact factor  
(Chronic Malignancies)



**2021 2022 2023**

<b>Oral presentations</b>	<b>7</b>	<b>9</b>	<b>9</b>
<b>Poster presentations</b>	<b>5</b>	<b>8</b>	<b>9</b>
<b>Educational events</b>	<b>2</b>	<b>2</b>	<b>2</b>

**Major educational events**



[Event](#)

## **49th Annual Meeting of the FBMF**



[Event](#)

## **Chronic Malignancies Working Party Educational Meeting 2023**

Jan 21, 2023 - Jan 21, 2023 / Virtual

Discover more

VISIT THE CMWP WEBPAGE